Real-Life Clinical Effectiveness of Razumab® (the World’s First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study | Zendy

Shashikant Sharma | Zendy; Mujtaba Khan | Zendy; Alok Chaturvedi | Zendy

Open Access

Real-Life Clinical Effectiveness of Razumab® (the World’s First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study

Author(s) -

Shashikant Sharma,

Mujtaba Khan,

Alok Chaturvedi

Publication year - 2018

Publication title -

ophthalmologica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.639

H-Index - 60

eISSN - 1423-0267

pISSN - 0030-3755

DOI - 10.1159/000488602

Subject(s) - ranibizumab , medicine , retinal vein , biosimilar , ophthalmology , central retinal vein occlusion , retrospective cohort study , occlusion , retinal , subgroup analysis , optometry , surgery , macular edema , bevacizumab , meta analysis , chemotherapy

This subgroup analysis of the RE-ENACT study evaluates the effectiveness of Razumab® (the world's first biosimilar of ranibizumab by Intas Pharmaceuticals Ltd.) in Indian patients with retinal vein occlusion (RVO).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research